UNCLAIMED
EXACT Sciences
Overview
Exact Sciences Corporation is a biotechnology company based in the USA, specializing in the development of innovative solutions for cancer screening and diagnostics, particularly in colorectal cancer (CRC). With approximately 6,900 employees and reported revenue of $2.759 billion, the company focuses on clinical laboratory services and advanced molecular diagnostics. A key area of expertise is the next-generation multi-target stool DNA (mt-sDNA) test, which is designed to improve the sensitivity and specificity of CRC screening compared to traditional fecal immunochemical tests (FIT). Recent studies indicate that the mt-sDNA test demonstrates higher sensitivity for detecting screening-relevant lesions, achieving a sensitivity of 93.9% for overall CRC and a specificity of 90.6% for advanced neoplasia. The technology is currently under development and has not yet received approval from the U.S. Food and Drug Administration (FDA). Exact Sciences aims to enhance early detection of colorectal cancer, thereby improving patient outcomes through its innovative diagnostic approaches.